Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 11/20 | 0.49 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL441098 | 0.89 | L3MBTL1 (0.55) | DGAT1L3MBTL1HPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL441311 | 0.87 | HPGD (0.55) | DGAT1HPGDALDH1A1GAA | |
| SCHEMBL441604 | 0.84 | DGAT1 (0.54) | DGAT1HPGD | |
| SCHEMBL437986 | 0.84 | DGAT1 (0.55) | DGAT1HPGD | |
| SCHEMBL440582 | 0.84 | DGAT1 (0.54) | DGAT1CYP2D6 | |
| SCHEMBL440637 | 0.83 | DGAT1 (0.53) | DGAT1HPGDALDH1A1SMN1; SMN2GAA | |
| SCHEMBL439353 | 0.82 | DGAT1 (0.48) | DGAT1HPGD | |
| SCHEMBL439993 | 0.82 | ALDH1A1 (0.60) | DGAT1HPGDALDH1A1GAA | |
| SCHEMBL14305144 | 0.81 | DGAT1 (0.53) | DGAT1CYP2D6 | |
| SCHEMBL463713 | 0.81 | DGAT1 (0.60) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | DGAT2, DGAT1, DLAT | DGAT1 2/4885CHRM4 4492/4885L3MBTL1 1197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.